Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) dropped 22 percent over the course of the day after reporting sales of its rare cholesterol disease drug that were much lower than analysts had expected. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) shares after opening at $36.25 moved to $36.55 on last trade day and at the end of the day closed at $34.63 . Company price to sales ratio in past twelve months was calculated as 21.05 and price to cash ratio as 8.09. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) showed a negative weekly performance of -21.76%.
Corcept Therapeutics Incorporated (NASDAQ:CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, reported its financial results for the quarter ended March 31, 2014. The company also reported that it is discontinuing its Phase 3 psychotic depression study (Study 14) based on the recommendation of the study’s data monitoring committee that the study was unlikely to meet its primary endpoint with statistical significance. Corcept Therapeutics Incorporated (NASDAQ:CORT) shares fell -50.50% in last trading session and ended the day on $1.99. CORT return on equity ratio is recorded as -128.50% and its return on assets is -60.90%. Corcept Therapeutics Incorporated (NASDAQ:CORT) yearly performance is 21.34%.
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)a clinical stage biopharmaceutical company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, announced that the Company will host a conference call and live audio webcast with an accompanying slide presentation at 8:00 a.m. EDT on Tuesday, May 13, 2014 to report its first quarter 2014 financial results. The Company will also provide a detailed review of its pipeline progress, business strategy, recent highlights and upcoming milestones. Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares moved down -7.78% in last trading session and was closed at $2.49 while trading in range of $2.45 – $2.77 – Idera Pharmaceuticals Inc (NASDAQ:IDRA) year to date (YTD) performance is -46.22%.
Cytokinetics Inc. (NASDAQ:CYTK) issued a press release announcing its results for the first quarter ended March 31, 2014. Cytokinetics, Inc. (NASDAQ:CYTK) weekly performance is -8.79%. On last trading day company shares ended up $4.15. Cytokinetics, Inc. (NASDAQ:CYTK) distance from 50-day simple moving average (SMA50) is -53.97%. Analysts mean target price for the company is $11.86.
Sangamo BioSciences, Inc. (NASDAQ:SGMO) reported first quarter 2014 financial results and accomplishments. For the first quarter ended March 31, 2014, Sangamo reported a consolidated net loss of $7.6 million, or $0.12 per share, compared to a net loss of $6.9 million, or $0.13 per share, for the same period in 2013. As of March 31, 2014, the Company had cash, cash equivalents, marketable securities and interest receivable of $244.2 million. Sangamo Biosciences, Inc. (NASDAQ:SGMO) shares after opening at $13.00 moved to $13.18 on last trade day and at the end of the day closed at $11.76 . Company price to sales ratio in past twelve months was calculated as 32.54 and price to cash ratio as 8.45. Sangamo Biosciences, Inc. (NASDAQ:SGMO) showed a negative weekly performance of -15.03%.
Leave a Reply